AZD0865
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
GERD With Erosive Esophagitis
Conditions
GERD With Erosive Esophagitis
Trial Timeline
May 1, 2004 → Mar 1, 2005
NCT ID
NCT00206245About AZD0865
AZD0865 is a phase 2 stage product being developed by AstraZeneca for GERD With Erosive Esophagitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00206245. Target conditions include GERD With Erosive Esophagitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00206245 | Phase 2 | Completed |
| NCT00206284 | Phase 2 | Completed |
Competing Products
20 competing products in GERD With Erosive Esophagitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rabeprazole ER + Ranitidine | Eisai | Phase 3 | 77 |
| Rabeprazole sodium | Eisai | Phase 1 | 33 |
| Rabeprazole sodium + Esomeprazole | Eisai | Phase 3 | 77 |
| rabeprazole sodium + Placebo | Eisai | Phase 3 | 77 |
| Rabeprazole ER + Ranitidine | Eisai | Phase 3 | 77 |
| Rabeprazole sodium 5 mg + Rabeprazole sodium 10 mg | Eisai | Phase 1 | 33 |
| rabeprazole + rabeprazole | Eisai | Phase 3 | 77 |
| Rabeprazole sodium + Esomeprazole | Eisai | Phase 3 | 77 |
| Rabeprazole sodium + Esomeprazole | Eisai | Phase 3 | 77 |
| ONO-8539 | Ono Pharmaceutical | Phase 1 | 33 |
| esomeprazole 40 mg | Johnson & Johnson | Pre-clinical | 23 |
| esomeprazole (Nexium®) + Xolaam® | AstraZeneca | Approved | 85 |
| esomeprazole | AstraZeneca | Pre-clinical | 23 |
| Esomeprazole | AstraZeneca | Approved | 85 |
| Esomeprazole | AstraZeneca | Approved | 85 |
| esomeprazole magnesium | AstraZeneca | Phase 1 | 33 |
| Esomeprazole | AstraZeneca | Approved | 85 |
| Esomeprazole | AstraZeneca | Phase 3 | 77 |
| Esomeprazole (Nexium) | AstraZeneca | Approved | 85 |
| Omeprazole | AstraZeneca | Phase 3 | 77 |